Dimerix strikes $120m licensing deal for kidney drug in Middle East
Dimerix sells exclusive rights to register and commercialise DMX-200 for the treatment of kidney disease in key Middle East countries Dimerix to receive up to ~$120.5m from Taiba in upfront and milestone payments, plus royalties Second deal executed for …